Prostate Cancer : A Complex Disease With Multiple Tumors

Today, prostate cancer is usually detected through screening, and there are two methods for early detection. The prostate-specific antigen test (PSA) is used, but there are

Another method to detect this cancer is with a Prostate Specific Antigen (PSA). Protein in the blood that is produced only by prostate cells is reflected the volume of both benign and malignant prostate tissue in the PSA. The higher the PSA level is the more likely it is that Prostate Cancer present. (“Prostate

Each year approximately 233,000 men will be diagnosed with prostate cancer (Eggener, Cifu, & Nabhan, 2015). In 2015, prostate cancer was the second most common cancer related cause of death among United States men (Eggener, et. al., 2015). While the majority of prostate cancers are slow growing with a 5-year survival rate of approximately 98%, statistics show that when prostate cancer is identified as metastatic, the 5-year survival rate dramatically drops down to 20-25% (Eggener, et. al., 2015). According to these numbers alone, it appears screening for prostate cancer would be a well-accepted practice. However, current methods of screening for this cancer are controversial and has lead organizations like the U.S Preventative Service Task Force (USPSTF) and the American Cancer Society (ACS) to different guidelines for screening.

A prostate is a gland in the male reproductive system found below the bladder and in front of the rectum. Prostate cancer is cancer that forms in tissue in that gland, it usually occurs in older men. Cancer comes in forms of tumors, which is an abnormal growth of cells. Malignant tumors are the cancerous tumors of the two different types of tumors. Can cause pain and interfere with normal function, but they can also cause other systems in the body to act abnormally. Malignant tumors can invade nearby groups of cells or tissues, crowding out and destroying normal cells.

Prostate cancer (PCa) is the commonest malignancy tumour in men and is second in cancer related death after lung cancer. PCa is mainly adenocarcinomas originating from the cortex of the gland (D’Elia et al. 2014).

Benign prostate hyperplasia (BPH) and prostate cancer share a few similarities, elevated prostate-specific antigen (PSA). Along with enlargement of prostate gland that causes urinary symptoms such as, frequent urination, hesitancy, dribbling, and frequent nighttime urination. However, they are quite different which is why more tests need to be done to confirm one or the other condition. These two diseases are also similar in the fact that they both cause an enlargement of the prostate. However with BPH the central portion of the prostate is enlarged and with prostate cancer more commonly the lateral lobes or side of the prostate are enlarged, but can affect any were on the prostate. Both can even be detected by a digital rectal exam however

Since tumor instability is not only seen between the primary and relapse setting but also throughout tumor progression, this makes clinical decisions more difficult and makes taking biopsies in a consecutive manner in the advanced setting a very important step to optimize treatment decision making for patients (Lindstrom et al,

TREATMENT of localized prostate cancer usually includes prostatectomy and radiation therapy, occasionally augmented with hormonal therapies. However, Fu et al., (2012) have noted that recurrence of prostate cancer occurs in about 15% of patients within 5 years after prostatectomy and in about 40% patients within 10 years. Although, more than 70% of patients are expected to survive for more than 10 years after prostatectomy, radiation or hormone therapy, Cooperberg et al.,(2010) argued that localized prostate cancer patients with intermediate or high risk scores have higher mortality rate after these treatments. With chemotherapies as the existing treatment options for metastatic prostate cancers, patients are expected to have only a median survival of 12-15 months. Bono et al.,(2006). However, most of these traditional treatments are invasive and riddled with adverse side effects. Therefore, novel therapies are on high demand for the treatment of the malignant and recurrent forms of prostate cancer after these

Prostate cancer is the second most common type of cancer diagnosed in men around the world today. Despite years of research, little is known as to the exact cause of prostate cancer, making it an area of intense research in medicine today. The pathology of prostate cancer has yielded important information on prevention, diagnosis and treatment methods. It has been understood that diet has much to do with tumour growth, and new research into nutrition is revealing new strategies in prostate cancer prevention. Genetics also play an important factor and must be taken into consideration. A number of new treatments for prostate cancer have been successfully implemented. Since prostate cancer is most common in men 50 and older, it is for the

Drug discovery is expensive and challenging. One such challenge is identifying clinically active cancer targets out of a huge number of biomolecules that are known to have a role in cancer initiation and progression. Below I have outlined the key information that should be gathered about a novel drug target, the experiments that are required to validate such a target, and discussed what needs to be considered when deciding whether a target has been validated.

Prostate cancer is the second most common cancer and it is the second leading cause of cancer death in American men according to the American Cancer Society(ACS) ( 2016). Older age is the strongest risk factor for the development of prostate cancer. Approximately 1 in 7 men will be diagnosed with prostate cancer during his lifetime (ACS, 2016). There are more than 2.9 million prostate cancer survivors in the United States (ACS, 2016). The risk of dying from prostate cancer is 2.9 percent, with seventy percent of deaths occurring after age 75(ACS, 2016; Howlader, Krapcho, Neyman,Aminou et al, 2011). The use of the prostate-specific antigen testing transformed prostate cancer screening in the 1990’s (Up to date) . PSA screening for prostate

The most accurate way to detect cancer cells inside the prostate gland is the surgical removal and histopathological examination of the entire gland. As this approach is clinically inapplicable to each patient with suspicious findings, Transrectal ultrasound (TRUS) guided prostatic biopsy is considered the standard diagnostic procedure for the detection of prostate cancer for patients with a high suspicion for prostate cancer 1.

Prostate cancer is abnormal cells that grow within the prostate gland and can spread to other body systems. Prostate cancer begins when cells in the prostate gland start to grow uncontrollably. The prostate is a gland found only in males. It makes some of the fluid that is part of semen. Prostate cancer is the second leading cause of cancer death in men in the United States and the fourth leading cause of death in black men overall. Studies show that black males are more than twice likely to die of prostate cancer than other counterparts.

Once again, unlike most cancers the signs of prostate cancer can develop very differently in each individual male as the cause of the cancer can also vary greatly. Due to these wide ranges of causes and symptoms, a number of different screening procedures may be required to clear or diagnose someone with prostate cancer. These screening

A prostate is a gland in the male reproductive system found below the bladder and in front of the rectum. Prostate cancer is cancer that forms in tissue in that gland, it usually occurs in older men. Cancer comes in forms of tumors, which is an abnormal growth of cells. Malignant tumors are the cancerous tumors of the two different types of tumors. Can cause pain and interfere with normal function, but they can also cause other systems in the body to act abnormally. Malignant tumors can invade nearby groups of cells or tissues, crowding out and destroying normal cells.